Table 4.
Risk-adjusted predictors of OS in WHO grade II oligodendroglioma patients
| Multivariate Cox Regression | |||
|---|---|---|---|
| HR | 95% CI | P-value | |
| Extent of Resection | |||
| Biopsy only | Reference | ||
| STR | 0.67 | (0.23–1.95) | 0.46 |
| GTR | 0.28 | (0.09–0.85) | 0.02 |
| Sex | |||
| Female (ref male) | 0.47 | (0.18–1.22) | 0.12 |
| Age, y | |||
| <40 | 0.54 | (0.11–2.65) | 0.45 |
| 40–49 | Reference | ||
| 50–59 | 1.76 | (0.49–6.37) | 0.39 |
| >60 | 2.89 | (0.59–14.17) | 0.19 |
| Year of diagnosis | |||
| 2010 | Reference | ||
| 2011 | 0.20 | (0.04–1.19) | 0.08 |
| 2012 | 0.72 | (0.16–3.27) | 0.67 |
| 2013 | 2.94 | (0.73–11.9) | 0.13 |
| 2014 | 1.42 | (0.26–7.86) | 0.69 |
| 2015 | 1.01 | (0.10–10.43) | 0.99 |
| Comorbidity index | |||
| 0 | Reference | ||
| 1 | 2.40 | (0.72–7.97) | 0.15 |
| 2 | 3.01 | (0.57–16.01) | 0.20 |
| Race/ethnicity | |||
| White, non-Hispanic | Reference | ||
| Nonwhite | 0.80 | (0.22–2.92) | 0.74 |
| Primary payor | |||
| Not insured | Reference | ||
| Private insurance | 0.24 | (0.06–0.92) | 0.04 |
| Medicare | 0.53 | (0.09–2.95) | 0.47 |
| Medicaid/other government | 0.22 | (0.02–2.23) | 0.20 |
| Tumor location | |||
| Frontal lobe | Reference | ||
| Temporal lobe | 0.64 | (0.32–1.28) | 0.21 |
| Parietal lobe | 1.05 | (0.53–2.06) | 0.89 |
| Other/Overlapping | 0.64 | (0.32–1.28) | 0.21 |
| Tumor size, cm | |||
| ≤2.0 | 0.97 | (0.10–9.03) | 0.98 |
| 2.1–4.0 | Reference | ||
| 4.1–6.0 | 0.91 | (0.23–3.65) | 0.90 |
| >6.0 | 4.56 | (1.27–16.4) | 0.02 |
| n/a | 2.15 | (0.62–7.47) | 0.23 |
| Facility type | |||
| Community cancer center | Reference | ||
| Academic/ NCI-designated | 1.13 | (0.36–3.55) | 0.84 |
| Integrated network care program | 0.65 | (0.06–6.62) | 0.72 |
| Suppressed due to age <40 y* | omitted due to collinearity | ||
NCI = National Cancer Institute.
*NCDB suppresses facility data for patients younger than 40 y to help ensure de-identification; as a result, in multivariable analysis, this factor is collinear with the age <40 y factor.